申请人:Schann Stephan
公开号:US20080027127A1
公开(公告)日:2008-01-31
The present invention relates to the use of trans pyrrolidinyl of the formula (I) or (II)
in which:
R
1
, R
2
or R
3
are hydrogen or a carboxy or amino protecting group; R
4
to R
8
represent hydrogen or an alkyl radical; R
9
represents a (R
10
)
n
(—R
11
)
m
group wherein R
10
is —CO—, —CS—, —O—, —S—, —SO—, —SO
2
—, —COO—, —CONR
a
—, —N(R
a
)CO—, —CSNR
a
—, —N(R
a
)CS—, —N(R
a
)—, R
b
, aryl, and R
11
is a polar group, for the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals.
本发明涉及使用式(I)或(II)的反式吡咯烷基,其中:R1、R2或R3为氢或羧基或氨基保护基;R4至R8表示氢或烷基基团;R9表示(R10)n(—R11)m基团,其中R10为—CO—、—CS—、—O—、—S—、—SO—、—SO2—、—COO—、—CONRa—、—N(Ra)CO—、—CSNRa—、—N(Ra)CS—、—N(Ra)—、Rb、芳基,而R11为极性基团,用于治疗和/或预防与改变谷氨酸能信号和/或功能相关的疾病和/或可以受到哺乳动物谷氨酸水平或信号改变影响的疾病。